Cooters & thread,
A strategic soundbite from the H&Q conference, courtesy of DoubleTwist:
>>Dr. Stuart Collinson, president and CEO of Aurora Biosciences (San Diego, CA), tried to make investors look at the high-throughput screening company in a new, broader light. "There is a genomic revolution taking place," he told the audience. "There is a land grab taking place, and if we don't show the kind of innovation we have in the past to get at the forefront of this land grab, we'll be missing a very big opportunity. We will not let that happen."
Aurora's past deals, Collinson acknowledged, involved milestones and nominal royalty payments "that are not where we'd like them to be." Future deals, he hopes, will involve more than the usual assay development and target screening; the company will use it's medicinal chemistry expertise and large compound libraries, in addition to assay development expertise, to get "a little further downstream in the discovery process," and deliver preclinical drug candidates to customers. "By getting into the compound side and getting the IP associated with compounds," he said, "we'll be able to…extract more value from our technologies."<<
snip
doubletwist.com
And the Amgen win makes the the IP angle look better now, too.
Cheers, Tuck |
